MarginsXMarginsX
Home › Markets › Health Care › GOVX

GeoVax Labs Inc. (GOVX)

GOVX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.02
+18.48% on the day
Market cap
$1.1M
Nano cap
Revenue · 2025
$2.5M
-37.1% on 2024
Net income · 2025
-$21.5M
-862.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/832489/000143774926012377/0001437749-26-012377-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerGOVX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000832489
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$2.5M
Net income-$21.5M
Operating income-$21.6M
Net margin-862.3%
Operating margin-869.3%
Revenue growth-37.1%
Cash$3.1M
Total assets$6.3M
P/E (computed)Net income was not positive
P/S (computed)0.4×

Warning signs

Cash runway
1.6 months
$2.2M cash at September 30, 2026
Share count, 1 year
+999.7%
2025-11-13 to 2026-11-12 · +18255.6% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$6K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors collectively raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-11-12
Cash and burn$2.2M cash; operating cash flow -$4.1M a quarter.Report 2026-09-30
Shares outstanding544,453 (2026-11-12); 29,705,360 a year earlier; 26,695,287 three years earlier. 1y figure adjusted for splits (1-for-600 overall); 3y figure adjusted for splits (1-for-9000 overall).Cover page 2026-11-12
Reverse splits, 3 years3; latest 1-for-24 on 2026-11-11Source 2026-11-11
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-02-17
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-08-28
Delisting25-NSE filed25-NSE 2025-09-29
AuditorWipfli LLP, Atlanta, Georgia, United StatesPCAOB Form AP 2026-04-21
Late filings, 12 months1 NT noticeNT 10-K 2026-03-31
Insider trades, 12 monthsBought $6K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$4.2M-$4.3M$2.2MNo debt tags$010-Q 2026-11-12
Q2 2026
2026-06-30
$0-$4.4M-$3.7M$3.1MNo debt tags$010-Q 2026-07-27
Q1 2026
2026-03-31
$0-$5.3M-$3.5M$1.3MNo debt tags$852K10-Q 2026-05-14
Q4 2025
2025-12-31
$0-$4.4M-$5.0M$3.1MNo debt tags$2.5M10-K 2026-04-15
Q3 2025
2025-09-30
$0-$6.3M-$6.2M$5.0MNo debt tags$3.4M10-Q 2026-11-12
Q2 2025
2025-06-30
$852K-$5.4M-$4.3M$3.1MNo debt tags$6.1M10-Q 2026-07-27
Q1 2025
2025-03-31
$1.6M-$5.4M-$6.0M$7.4MNo debt tags$5.6M10-Q 2026-05-14
Q4 2024
2024-12-31
$864K-$8.3M-$7.8M$5.5MNo debt tags$4.0M10-K 2026-04-15

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM S-1
S-12026-11-04
Latest annual report
FORM 10-K
10-K2026-04-15
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-12
Latest current report
FORM 8-K
8-K2026-11-12
Latest proxy
FORM DEF 14A
DEF 14A2026-09-10

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-55.0%
1 month-73.3%
3 months-90.1%
Year to date-98.3%
1 year-99.4%
From 52-week high-99.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BDRXBiodexa Pharmaceuticals plc American Depositary Shs$2.24-6.28%$1.2M
MTNBMatinas Biopharma Holdings Inc.$0.9270+3.00%$908K
ELABPMGC Holdings Inc.$1.66+5.06%$1.3M
OGENOragenics Inc.$0.1980-1.49%$893K
KAPAKairos Pharma Ltd.$0.4069-10.30%$1.4M
APVOAptevo Therapeutics Inc.$0.5486-7.66%$1.5M
SPRCSciSparc Ltd.$0.3307-10.62%$815K
ARTLArtelo Biosciences Inc.$1.70-17.87%$1.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier